Sabiston Ch50 - Diverticular Disease & Miscellaneous Problems

Citation: Sabiston Textbook of Surgery, Chapter 50 “Small Intestine” (authors: Tong Gan, B. Mark Evers). Source file: raw/Sabiston Ch50 - Small Intestine.pdf, pages 46–61 of 61 (chunk 3, the final chunk of the chapter).

Type: Textbook reference chapter — narrative background/orientation, not critically-appraised primary literature. Content is filed as reference and flagged as such throughout.

Scope of this chunk

• Additional GIST prognostic/mutation detail and advanced/metastatic medical therapy (dasatinib, regorafenib, nilotinib, sorafenib) — merged into Gastrointestinal Stromal Tumors (GIST)
• Metastatic neoplasms to the small bowel (melanoma most common extraabdominal source) — merged into Small Bowel Neoplasms
• Diverticular disease: duodenal, jejunal/ileal, and Meckel diverticula — new Small Bowel Diverticular Disease overview plus Duodenal Diverticula, Jejunal and Ileal Diverticula, and Meckel Diverticulum detail pages
• Miscellaneous problems: small bowel ulcerations, ingested foreign bodies, enterocutaneous fistula, pneumatosis intestinalis, blind loop syndrome, radiation enteritis, short bowel syndrome, and vascular compression of the duodenum (SMA/Wilkie syndrome) — seven new condition pages

This chunk completes the entire Sabiston “Small Intestine” chapter (61 pages across 3 chunks) and was the final source in the wiki’s original planned ingest list.

Key points

• GIST mutation-directed therapy: D842V PDGFRα mutations predict resistance to adjuvant imatinib; exon 9 mutations respond better to double-dose (800 mg) imatinib. Second-line agents after imatinib/sunitinib failure include regorafenib (FDA-approved), dasatinib, nilotinib, and sorafenib.
• Metastatic melanoma is the most common extraabdominal source of small bowel metastasis, found in >50% of patients dying of the disease.
• Duodenal diverticula are the most common acquired small bowel diverticula; Meckel diverticulum is the most common true congenital diverticulum.
• Meckel diverticulum malignancy risk: a population-based study found the ileal cancer risk in a Meckel diverticulum ~70-fold higher than any other ileal site — a genuinely unresolved controversy exists in the literature over whether to resect incidentally found diverticula (Soltero and Bill’s historical ≤2% symptomatic-conversion estimate vs. more recent malignancy-risk-driven arguments for resection).
• Enterocutaneous fistula: 75–85% are iatrogenic (surgical). Three-phase management — stabilization, staging/supportive care, definitive surgery. Most fistulas that close do so within 1 month; if not closed by 3 months, spontaneous closure is unlikely.
• Pneumatosis intestinalis is explicitly emphasized as “a radiographic finding, not a diagnosis” — treatment targets the underlying cause, not the pneumatosis itself.
• Short bowel syndrome: up to 70% of small bowel can usually be tolerated if the terminal ileum and ileocecal valve are preserved. Teduglutide (GLP-2 analogue) is the first targeted therapeutic agent approved for short bowel syndrome with intestinal failure.

Limitations

• Narrative textbook chapter; several claims (Meckel malignancy risk study, enterocutaneous fistula closure-rate study, teduglutide/growth-hormone trial data, radiation enteritis prevention agents) cite single studies without independent appraisal here.
• The chapter’s own “Selected References” section (not otherwise transcribed into this wiki) flags several of these — e.g., the Zani et al. Meckel diverticulum systematic review and the Soltero/Bill historical series — as genuinely contested areas warranting further reading if clinically relevant.

Relevance

Completes the expansion of Gastrointestinal Stromal Tumors (GIST) and Small Bowel Neoplasms; backs the new Small Bowel Diverticular Disease, Duodenal Diverticula, Jejunal and Ileal Diverticula, Meckel Diverticulum, Small Bowel Ulcerations, Ingested Foreign Bodies, Enterocutaneous Fistula, Pneumatosis Intestinalis, Blind Loop Syndrome, Radiation Enteritis, Short Bowel Syndrome, and Vascular Compression of the Duodenum (SMA Syndrome) pages. This is the last chunk of the last originally planned source — see wiki/Overview.md for the ingest-completion note.